Philadelphia Business Journal: Former Spark executives steering Nava Therapeutics to ‘extraordinary progress

Nava Therapeutics is embarking on a Series B financing round as the biotechnology firm pursues human clinical testing of its delivery platform of genetic medicines. Nava is developing new ways to deliver genetic medicines directly into the body, with the goal of treating diseases by changing patients’ genes rather than relying on traditional drugs. The company is focused on developing a proprietary lipid nanoparticle platform to deliver RNA-based genetic medicines.